Close

Ultragenyx Pharma (RARE) Announces Presentations Highlighting KRN23 at ASBMR Meeting

Go back to Ultragenyx Pharma (RARE) Announces Presentations Highlighting KRN23 at ASBMR Meeting

Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting

August 23, 2016 8:30 AM EDT

NOVATO, Calif., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting taking place September 16-19 in Atlanta, Georgia.

Two oral presentations will highlight 40-week (n=52) and 64-week (n=36) data from the Phase 2 pediatric XLH study, as well as results from the ongoing Phase 2 TIO study:

... More